Shares of Bruker Corporation (NASDAQ:BRKR) have been assigned a consensus recommendation of “Hold” from the fourteen research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $27.00.

Several research analysts have recently commented on the company. BidaskClub upgraded Bruker Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, August 16th. Barclays PLC reiterated an “equal weight” rating and issued a $30.00 price objective (up previously from $26.00) on shares of Bruker Corporation in a report on Monday, July 17th. Cowen and Company reiterated a “hold” rating and issued a $29.00 price objective on shares of Bruker Corporation in a report on Friday, July 14th. Wells Fargo & Company downgraded Bruker Corporation from a “market perform” rating to an “underperform” rating in a report on Wednesday, July 12th. Finally, Zacks Investment Research upgraded Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a report on Thursday, July 6th.

In other Bruker Corporation news, CEO Frank H. Laukien purchased 2,335 shares of Bruker Corporation stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average price of $27.39 per share, for a total transaction of $63,955.65. Following the acquisition, the chief executive officer now directly owns 37,791,386 shares in the company, valued at $1,035,106,062.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, VP Mark Munch sold 21,061 shares of the business’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total value of $631,198.17. Following the transaction, the vice president now owns 60,524 shares in the company, valued at approximately $1,813,904.28. The disclosure for this sale can be found here. 35.20% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in BRKR. Acrospire Investment Management LLC boosted its position in Bruker Corporation by 496.1% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock valued at $110,000 after acquiring an additional 3,185 shares in the last quarter. SG Americas Securities LLC bought a new stake in Bruker Corporation during the 2nd quarter valued at approximately $111,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Bruker Corporation by 11.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock valued at $133,000 after acquiring an additional 467 shares in the last quarter. Smithfield Trust Co. bought a new stake in Bruker Corporation during the 2nd quarter valued at approximately $138,000. Finally, The Manufacturers Life Insurance Company boosted its position in Bruker Corporation by 7.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock valued at $144,000 after acquiring an additional 331 shares in the last quarter. Institutional investors own 65.42% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was posted by Daily Political and is owned by of Daily Political. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/09/19/bruker-corporation-brkr-receives-27-00-consensus-price-target-from-brokerages.html.

Shares of Bruker Corporation (BRKR) traded down 0.27% during midday trading on Friday, hitting $30.04. The stock had a trading volume of 88,360 shares. The firm’s 50-day moving average price is $28.54 and its 200-day moving average price is $26.53. The stock has a market cap of $4.77 billion, a price-to-earnings ratio of 29.95 and a beta of 1.10. Bruker Corporation has a 1-year low of $19.59 and a 1-year high of $30.23.

Bruker Corporation (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.03. The firm had revenue of $414.90 million for the quarter, compared to the consensus estimate of $384.75 million. Bruker Corporation had a return on equity of 26.66% and a net margin of 9.65%. The company’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.20 earnings per share. Analysts forecast that Bruker Corporation will post $1.12 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 22nd. Investors of record on Tuesday, September 5th will be issued a dividend of $0.04 per share. The ex-dividend date is Thursday, August 31st. This represents a $0.16 dividend on an annualized basis and a yield of 0.53%. Bruker Corporation’s dividend payout ratio is presently 16.00%.

Bruker Corporation Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker Corporation (NASDAQ:BRKR)

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.